A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Phase of Trial: Phase III
Latest Information Update: 24 Sep 2017
At a glance
- Drugs Esaxerenone (Primary) ; Eplerenone
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ESAX-HTN
- Sponsors Daiichi Sankyo Company
- 24 Sep 2017 According to an Exelixis media release, Daiichi Sankyo will submit a Japanese regulatory application for esaxerenone for an essential hypertension indication in the first quarter of 2018.
- 24 Sep 2017 According to an Exelixis media release, Daiichi Sankyo plans to disclose the detailed study results at future scientific meetings.
- 24 Sep 2017 Primary endpoint Change from baseline in sitting systolic and diastolic blood pressure has been met according to an Exelixis media release.